Page last updated: 2024-12-11

sb 269970

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SB 269970: a 5-HT(7) antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6604889
CHEMBL ID282199
CHEBI ID92426
SCHEMBL ID375474
MeSH IDM0358504

Synonyms (48)

Synonym
tocris-1612
NCGC00025229-01 ,
LOPAC0_001059
pyrrolidine, 1-((3-hydroxyphenyl)sulfonyl)-2-(2-(4-methyl-1-piperidinyl)ethyl)-, (r)-
sb 269970
NCGC00025229-02
NCGC00025229-03
CHEMBL282199 ,
sb-269970
(r)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl)phenol
3-{2-[2-(4-methyl-piperidin-1-yl)-ethyl]-pyrrolidine-1-sulfonyl}-phenol
bdbm50098551
3-{2-[2-(4-methyl-piperidin-1-yl)-ethyl]-pyrrolidine-1-sulfonyl}-phenol (sb-269970)
(r)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidin-1-ylsulfonyl)phenol
3-{(s)-2-[2-(4-methyl-piperidin-1-yl)-ethyl]-pyrrolidine-1-sulfonyl}-phenol
3-{(r)-2-[2-(4-methyl-piperidin-1-yl)-ethyl]-pyrrolidine-1-sulfonyl}-phenol
3-[(2r)-2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidin-1-yl]sulfonylphenol
unii-kc8kp5xu6f
kc8kp5xu6f ,
CCG-205136
201038-74-6
BCPP000080
sb-269,970
3-[(2r)-2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulfonyl]phenol
gtpl3247
gtpl3233
sb269970
[3h]sb269970
sb-269970-a
CS-1645
HY-15370
SCHEMBL375474
(r)-3-((2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidin-1-yl)sulfonyl)phenol
AKOS024465019
CHEBI:92426
(r)-3-(2-(2-(4-methylpiperidin-1-yl)-ethyl)pyrrolidine-1-sulfonyl)phenol
DB13988
DTXSID90942127
3-({(2r)-2-[2-(4-methyl-1-piperidinyl)ethyl]-1-pyrrolidinyl}sulfonyl)phenol
Q1427742
BRD-K24201553-003-02-4
SDCCGSBI-0051029.P002
NCGC00025229-12
phenol, 3-[[(2r)-2-[2-(4-methyl-1-piperidinyl)ethyl]-1-pyrrolidinyl]sulfonyl]-
TQP0828
3-((2r)-2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidin-1-yl)sulfonylphenol
pyrrolidine, 1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl]-, (r)-
(r)-1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl]pyrrolidine

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Treatment with SB 269970 did not affect membrane excitability of pyramidal cells."( Repeated blockade of 5-HT₇ receptors depresses glutamatergic transmission in the rat frontal cortex.
Hess, G; Kusek, M; Tokarski, K, 2012
)
0.72

Bioavailability

ExcerptReferenceRelevance
"8% oral bioavailability and good penetration to the brain."( Novel N-acyl-carbazole derivatives as 5-HT7R antagonists.
Choo, H; Kim, Y; Rhim, H; Tae, J; Yeom, M, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
"2 microg) and higher doses (2 and 5 microg) of SB-269970-A were less effective, indicating a bell-shaped dose-response curve."( 5-HT7 receptor subtype as a mediator of the serotonergic regulation of luteinizing hormone release in the zona incerta.
Abu-Amara, M; Aldairy, C; Hagan, JJ; Siddiqui, A; Wilson, C, 2004
)
0.32
" Dosed in vivo, escitalopram had little impact on the occurrence of activity onsets in rats given access to running wheels, whether the drug was given acutely or sub-chronically."( The effects of combining serotonin reuptake inhibition and 5-HT7 receptor blockade on circadian rhythm regulation in rodents.
Sánchez, C; Sprouse, J; Westrich, L, 2013
)
0.39
" The novel 5-HT7R antagonist 1-8 exhibited an antidepressant effect at a dose of 25mg/kg in the forced swimming test in mice and showed a U-shaped dose-response curve which typically appears in 5-HT7R antagonists such as SB-269970 and lurasidone."( Novel N-biphenyl-2-ylmethyl 2-methoxyphenylpiperazinylalkanamides as 5-HT7R antagonists for the treatment of depression.
Cho, H; Choo, H; Choo, IH; Keum, G; Kim, Y; Lee, K; Park, WK; Rhim, H; Tae, J, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.48020.100020.879379.4328AID588453; AID588456
regulator of G-protein signaling 4Homo sapiens (human)Potency1.50090.531815.435837.6858AID504845
arylsulfatase AHomo sapiens (human)Potency0.01901.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency25.11890.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency7.94330.00207.533739.8107AID891
lethal factor (plasmid)Bacillus anthracis str. A2012Potency0.10000.020010.786931.6228AID912
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency42.56150.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)Ki0.00500.00011.48339.1400AID1324270
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki8.20770.00010.532610.0000AID1188131; AID1193845; AID1324269; AID1336983; AID1546007; AID1627081; AID1769140; AID3926; AID4108; AID694795
D(2) dopamine receptorHomo sapiens (human)Ki0.31610.00000.651810.0000AID63249; AID65736
5-hydroxytryptamine receptor 1DHomo sapiens (human)Ki5.79240.00010.808710.0000AID1769142; AID4651
5-hydroxytryptamine receptor 1BHomo sapiens (human)Ki5.50000.00010.54859.2100AID1769141; AID4279
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki6.66830.00000.385510.0000AID1324270; AID1769144; AID5424
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki6.66830.00010.954910.0000AID1324273; AID1769146; AID5655
5-hydroxytryptamine receptor 1EHomo sapiens (human)Ki8.15480.09304.770110.0000AID1769143; AID4957
5-hydroxytryptamine receptor 1FHomo sapiens (human)Ki3.16230.00161.786510.0000AID4989
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Ki0.00110.00000.14803.1800AID238569; AID6654
5-hydroxytryptamine receptor 7Homo sapiens (human)IC50 (µMol)0.00190.00050.45464.7640AID1330693; AID1380718; AID1384702; AID1545645; AID1769135
5-hydroxytryptamine receptor 7Homo sapiens (human)Ki0.00090.00030.380610.0000AID1187932; AID1188130; AID1193846; AID1278620; AID1324271; AID1330689; AID1336982; AID1384578; AID1384657; AID1517164; AID1546006; AID1627080; AID1769134; AID433130; AID552758; AID628897; AID6595; AID6609; AID6614; AID6677; AID694794; AID745115
Alpha-1B adrenergic receptorHomo sapiens (human)Ki10.00000.00000.471310.0000AID35178
D(3) dopamine receptorHomo sapiens (human)Ki2.51190.00000.602010.0000AID65313
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki6.66830.00030.769310.0000AID1324272; AID1769145; AID5775
5-hydroxytryptamine receptor 3AHomo sapiens (human)Ki10.00000.00000.74119.9000AID1769147
5-hydroxytryptamine receptor 5AHomo sapiens (human)Ki0.04300.00080.94335.1600AID1769149; AID6474; AID6486
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki8.15480.00020.522910.0000AID1769150; AID6539
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.06500.00000.437510.0000AID6474
5-hydroxytryptamine receptor 4Homo sapiens (human)Ki5.62950.00000.443910.0000AID1769148; AID6463
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 7Homo sapiens (human)Kd0.00970.00970.04460.0794AID608459
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1BHomo sapiens (human)Kb0.00100.00100.00100.0010AID1193852
5-hydroxytryptamine receptor 7Homo sapiens (human)Kb0.00060.00010.00200.0110AID1152673; AID1380718; AID1545641; AID1740901
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (208)

Processvia Protein(s)Taxonomy
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of locomotion5-hydroxytryptamine receptor 1DHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1DHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of gamma-aminobutyric acid secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of serotonin secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, GABAergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to cocaine5-hydroxytryptamine receptor 1BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1BHomo sapiens (human)
drinking behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to ethanol5-hydroxytryptamine receptor 1BHomo sapiens (human)
bone remodeling5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to mineralocorticoid5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to alkaloid5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to xenobiotic stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration5-hydroxytryptamine receptor 1BHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of synaptic vesicle exocytosis5-hydroxytryptamine receptor 1BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1BHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1EHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1EHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1EHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1EHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1EHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1FHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1FHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1FHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1FHomo sapiens (human)
smooth muscle contraction5-hydroxytryptamine receptor 7Homo sapiens (human)
circadian rhythm5-hydroxytryptamine receptor 7Homo sapiens (human)
blood circulation5-hydroxytryptamine receptor 7Homo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 7Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1B adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of cardiac muscle contractionAlpha-1B adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1B adrenergic receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3AHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
hippocampus development5-hydroxytryptamine receptor 5AHomo sapiens (human)
response to estradiol5-hydroxytryptamine receptor 5AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 5AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 5AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
maintenance of gastrointestinal epithelium5-hydroxytryptamine receptor 4Homo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 4Homo sapiens (human)
mucus secretion5-hydroxytryptamine receptor 4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
large intestinal transit5-hydroxytryptamine receptor 4Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (28)

Processvia Protein(s)Taxonomy
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels5-hydroxytryptamine receptor 1BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor activity5-hydroxytryptamine receptor 1EHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1EHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1EHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1EHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1EHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1FHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1FHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1FHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
protein bindingAlpha-1B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1B adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1B adrenergic receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 5AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 5AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 5AHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 4Homo sapiens (human)
serotonin receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (44)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1DHomo sapiens (human)
endoplasmic reticulum5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
calyx of Held5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonergic synapse5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 1BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1EHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1EHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1FHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1FHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1FHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1FHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
trans-Golgi network membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
synapse5-hydroxytryptamine receptor 7Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
nucleusAlpha-1B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
caveolaAlpha-1B adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
cleavage furrow5-hydroxytryptamine receptor 3AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
perikaryon5-hydroxytryptamine receptor 5AHomo sapiens (human)
postsynaptic specialization membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 5AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 4Homo sapiens (human)
endosome5-hydroxytryptamine receptor 4Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
synapse5-hydroxytryptamine receptor 4Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (177)

Assay IDTitleYearJournalArticle
AID1384699Sleep promoting activity in C57B1/6J mouse assessed as decrease in total rapid eye movement sleep time at 30 mg/kg, ip measured over 8 hrs by electroencephalogram method
AID1380715Agonist activity at human 5-HT7 receptor expressed in CHO-K1 cells assessed as increase in serotonin-induced cAMP level after 1 hr by TR-FRET assay relative to serotonin
AID1274963Antidepressant activity in C57BL/6J mouse assessed as immobility time at 5 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 160.7 +/- 12 to 170.6 +/- 9 sec)2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1769134Displacement of [3H]-LSD from 5HT7 receptor (unknown origin) transfected in HEK293 cells incubated for 1.5 hrs by liquid scintillation counting2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID1188130Displacement of [3H]5-HT from human 5HT7 receptor transfected in CFO-K1 cells after 30 mins by liquid scintillation spectrometry2014European journal of medicinal chemistry, Oct-06, Volume: 85Structure-activity relationships and molecular modeling studies of novel arylpiperazinylalkyl 2-benzoxazolones and 2-benzothiazolones as 5-HT(7) and 5-HT(1A) receptor ligands.
AID1364787Cognitive enhancement effect in Sprague-Dawley rat memory impairment model assessed as reversal of natural forgetting impairment at 1 mg/kg, ip administered 30 mins prior to test measured after 24 hrs by novel object recognition test
AID763804Antagonist activity at human recombinant 5HT7 receptor expressed in HEK293 cells assessed as inhibition of 5HT-induced cAMP accumulation at 10 uM pretreated for 10 mins before 5HT addition measured after 1 hr relative to control2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Design and synthesis of novel series of 5-HT6 receptor ligands having indole, a central aromatic core and 1-amino-4 methyl piperazine as a positive ionizable group.
AID1690400Antagonist activity at recombinant human 5HT7 receptor expressed in CHO-K1 cells assessed as inhibition of serotonin-induced cAMP accumulation measured after 1 hr by LANCE TR-FRET assay2020European journal of medicinal chemistry, Apr-01, Volume: 191Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD).
AID6486Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID433130Binding affinity to human cloned 5HT7 receptor expressed in HEK293 cells2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Sulfonamides with the N-alkyl-N'-dialkylguanidine moiety as 5-HT7 receptor ligands.
AID1384706Antagonist activity at tTA containing TCS cleavage site-fused 5-HT7 receptor (unknown origin) expressed in tTA-dependent luciferase reporter/TEV-fused beta-arrestin2 expressing HTLA cells assessed as inhibition of 5-HT-induced beta-arrestin2 recruitment a
AID296895Antagonist activity at 5HT7 receptor in guinea pig ileum assessed as effect on 6-(4-(2-chlorophenyl)piperazine-1-yl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide mediated relaxation of substance P-induced contraction2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
AID1769146Binding affinity to 5HT2C receptor (unknown origin)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID1274949Antidepressant activity in C57BL/6J mouse assessed as average force at 5 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 0.281 +/- 0.018 to 0.359 +/- 0.027 N)2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1274954Antidepressant activity in C57BL/6J mouse assessed as number of events at 1.25 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 1325.1 +/- 77.8 to 1773.4 +/- 109.9 No_unit)2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1380718Antagonist activity at human 5-HT7 receptor expressed in CHO-K1 cells assessed as decrease in serotonin-induced cAMP level after 1 hr by TR-FRET assay
AID296894Antagonist activity at 5HT7 receptor in guinea pig ileum assessed as effect on 6-(4-(2-nitrophenyl)piperazin-1-yl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide mediated relaxation of substance P-induced contraction2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
AID6595Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
1-(Bicyclopiperazinyl)ethylindoles and 1-(homopiperazinyl)ethyl-indoles as highly selective and potent 5-HT(7) receptor ligands.
AID1274945Toxicity in ip dosed C57BL/6J mouse assessed as effect on spontaneous locomotory activity at MED measured over 1 min 15 secs2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID242914Effect on basal adenylate cyclase activity relative to potency of methiothepin using rat 5-HT7 receptor expressed in HEK cells; ND=Not determined2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides.
AID608459Binding affinity to 5HT7 receptor2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Synthesis and biological evaluation of potential 5-HT(7) receptor PET radiotracers.
AID4651Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID694794Displacement of [3H]-5-CT from human 5-HT7b receptor expressed in HEK293 cells after 1 hr2012European journal of medicinal chemistry, Oct, Volume: 56The multiobjective based design, synthesis and evaluation of the arylsulfonamide/amide derivatives of aryloxyethyl- and arylthioethyl- piperidines and pyrrolidines as a novel class of potent 5-HT₇ receptor antagonists.
AID6614Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID628897Displacement of [3H]-5-CT from human 5-HT7 receptor expressed in HEK293 cells after 1 hr by liquid scintillation counting2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands.
AID296897Antagonist activity at 5HT7 receptor in guinea pig ileum assessed as effect on 4-(2-diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazine hexanamide mediated relaxation of substance P-induced contraction2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
AID1274955Antidepressant activity in C57BL/6J mouse assessed as number of events at 2.5 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 1325.1 +/- 77.8 to 1773.4 +/- 109.9 No_unit)2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1336984Antagonist activity at recombinant human 5-HT7 receptor expressed in HEK293 cells assessed as inhibition of 5-CT-induced increase in cAMP level at 10'-6M after 30 mins by TR-FRET assay relative to control2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
New N- and O-arylpiperazinylalkyl pyrimidines and 2-methylquinazolines derivatives as 5-HT
AID6474Binding affinity towards 5-hydroxytryptamine 5 receptor2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
AID1769169Effect on shank3-/- mouse model of autism spectrum disorder assessed as reduction in number of self grooming at 5 mg/kg, ip after 30 mins (Rvb = 33.6 +/- 3.1 No_unit)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID1364789Antidepressant-like activity in C57BL/6J mouse assessed as decrease in immobility time at 1.25 to 10 mg/kg cotreated with dopamine reuptake inhibitor GBR-12909 measured during 6 mins session by tail suspension test
AID1274943Toxicity in ip dosed C57BL/6J mouse assessed as effect on spontaneous locomotory activity at MED measured over 6 mins2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1740901Antagonist activity at recombinant human 5HT7 receptor expressed in CHO-K1 cells co-transfected with beta-lactamase reporter gene assessed as inhibition of serotonin-induced cAMP accumulation measured after 1 hr by LANCE TR-FRET assay
AID1269158Toxicity in Swiss albino mouse assessed as effect on spontaneous locomotor activity at 10 mg/kg, ip dosed 30 mins before test measured after 2 to 6 mins2016Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2
N-Alkylated arylsulfonamides of (aryloxy)ethyl piperidines: 5-HT(7) receptor selectivity versus multireceptor profile.
AID1330693Antagonist activity at human 5-HT7R expressed in HEK293 cells assessed as inhibition of serotonin stimulated-cAMP levels preincubated for 10 mins followed by serotonin stimulation after 30 mins by D2-dye based fluorescence assay2016European journal of medicinal chemistry, Nov-10, Volume: 1235-HT7 receptor modulators: Amino groups attached to biphenyl scaffold determine functional activity.
AID1274940Antidepressant activity in ip dosed C57BL/6J mouse assessed as reduction in immobility time of mouse by tail suspension test2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1274941Antidepressant activity in ip dosed Wistar rat assessed as reduction in immobility time of rat by forced swim test2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1769143Binding affinity to 5HT1E receptor (unknown origin)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID6539Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID628906Neurotoxicity in Albino Swiss mouse assessed as effect on number of crossings at 10 mg/kg, ip administered 30 mins before test measured for 2 to 6 mins2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands.
AID1384657Displacement of [3H]LSD from human 5-HT7 receptor expressed in HEK cell membranes after 1.5 hrs by microbeta scintillation counting method
AID6609Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.
AID63249Binding affinity towards Dopamine receptor D2 (human cloned receptor) in CHO cells using [125I]iodosulpiride radioligand.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID1769142Binding affinity to 5HT1D receptor (unknown origin)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID1769166Effect on wild type mouse assessed as reduction in duration of self grooming at 5 mg/kg, ip after 30 mins (Rvb = 65 +/- 3.3 sec)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID1517165Displacement of [3H]-8-OH-DPAT from human 5-HT1A receptor expressed in CHO-K1 cells incubated for 60 mins by liquid scintillation counting method2019European journal of medicinal chemistry, Dec-01, Volume: 183[1]Benzothieno[3,2-d]pyrimidine derivatives as ligands for the serotonergic 5-HT
AID1545641Antagonist activity at human recombinant 5-HT7 receptor expressed in CHOK1 cells assessed as equilibrium binding constant measured after 60 mins in the presence of serotonin by LANCE TR-FRET assay2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
AID628907Neurotoxicity in Albino Swiss mouse assessed as effect on number of crossings at 10 mg/kg, ip administered 30 mins before test measured for 30 mins2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands.
AID1627080Displacement of [3H]-5-HT from human 5-HT7 receptor expressed in CHOK1 cell membranes after 30 mins by liquid scintillation spectrometry2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Design and synthesis of new homo and hetero bis-piperazinyl-1-propanone derivatives as 5-HT7R selective ligands over 5-HT1AR.
AID1274964Antidepressant activity in C57BL/6J mouse assessed as immobility time at 10 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 160.7 +/- 12 to 170.6 +/- 9 sec)2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1769135Antagonist activity at human 5-HT7 receptor expressed in HEK293 cells assessed as reduction in cAMP accumulation incubated for 30 mins by microplate reader analysis2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID1187932Displacement of [3H]LSD from 5-HT7R (unknown origin) expressed in CHO-K1 cells by liquid scintillation counting method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Novel N-biphenyl-2-ylmethyl 2-methoxyphenylpiperazinylalkanamides as 5-HT7R antagonists for the treatment of depression.
AID1330689Displacement of [3H]D-lysergic acid diethylamide from 5HT7R (unknown origin) expressed in HEK293 cell membranes incubated for 1.5 hrs in absence of light by liquid scintillation counting2016European journal of medicinal chemistry, Nov-10, Volume: 1235-HT7 receptor modulators: Amino groups attached to biphenyl scaffold determine functional activity.
AID1274942Anxiolytic activity in ip dosed albino Swiss mouse assessed as increase in number of shocks accepted measured over 1 min, 15 secs by four plates test2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1274947Antidepressant activity in C57BL/6J mouse assessed as average force at 1.25 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 0.281 +/- 0.018 to 0.359 +/- 0.027 N)2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1274970Toxicity in ip dosed albino Swiss mouse assessed as effect on spontaneous locomotory activity at MED measured over 2 to 6 mins2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID237427Partition coefficient (logP)2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides.
AID1384710Sleep promoting activity in C57B1/6J mouse assessed as duration of total non-rapid eye movement sleep time at 30 mg/kg, ip measured over 8 hrs by electroencephalogram method (Rvb = 252 +/- 22.7 mins)
AID1278620Displacement of [3H]LSD from 5-HT7 receptor (unknown origin) expressed in CHO-K1 cells by liquid scintillation counting method2016European journal of medicinal chemistry, Mar-03, Volume: 110Novel N-acyl-carbazole derivatives as 5-HT7R antagonists.
AID1324273Displacement of [3H]-mesulergine from human 5-HT2C receptor expressed in HEK293 cells2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.
AID1193845Displacement of [3H]-5-HT from human 5-HT1A receptor expressed in CHOK1 cells after 30 mins by liquid scintillation counting analysis2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis and binding properties of new long-chain 4-substituted piperazine derivatives as 5-HT₁A and 5-HT₇ receptor ligands.
AID699060Antagonist activity at human 5HT7A receptor expressed in human HeLa cells assessed as inhibition of forskolin-induced cAMP accumulation by ELISA2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Investigations on the 1-(2-biphenyl)piperazine motif: identification of new potent and selective ligands for the serotonin(7) (5-HT(7)) receptor with agonist or antagonist action in vitro or ex vivo.
AID1384702Antagonist activity at human 5-HT7 receptor expressed in HEK293 cells assessed as inhibition of Gs protein-mediated cAMP accumulation by luminescence-based assay
AID1374551Antidepressant-like activity in Wistar rat assessed as decrease in immobility time at 2.5 mg/kg, ip administered 30 mins prior to test measured for 5 mins by forced swim test2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
AID1187936Antagonist activity against human 5-HT7R expressed in HEK293 cells assessed as reduction in 5-HT-induced cAMP accumulation at 10 uM pre-treated for 10 mins before 5-HT challenge for 30 mins by fluorescence assay2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Novel N-biphenyl-2-ylmethyl 2-methoxyphenylpiperazinylalkanamides as 5-HT7R antagonists for the treatment of depression.
AID1274956Antidepressant activity in C57BL/6J mouse assessed as number of events at 5 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 1325.1 +/- 77.8 to 1773.4 +/- 109.9 No_unit)2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1817201Effect on shank3-/- mouse model of autism spectrum disorder assessed as time taken for duration of self grooming at 30 mg/kg, ip after 30 mins under 40 lux lighting (Rvb = 224 +/- 47.4 sec)2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of G Protein-Biased Ligands against 5-HT
AID1384705Agonist activity at tTA containing TCS cleavage site-fused 5-HT7 receptor (unknown origin) expressed in tTA-dependent luciferase reporter/TEV-fused beta-arrestin2 expressing HTLA cells assessed as induction of beta-arrestin2 recruitment after 22 hrs by Ta
AID1324269Displacement of [3H]-8-OH-DPAT from human 5-HT1A receptor expressed in HEK293 cells2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.
AID1769137Antagonist activity at human 5-HT7 receptor expressed in HEK293 cells assessed as reduction in cAMP accumulation incubated for 30 mins by microplate reader analysis relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID628902Antidepressant like activity in Albino Swiss mouse assessed as reduction of immobility time at 5 mg/kg, ip administered 30 mins before test measured during final 4 mins of the 6 mins session by forced swimming test (Rvb = 165 +/- 9.6 sec)2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands.
AID327997Antagonist activity at human 5HT7A receptor expressed in CHO cells assessed as inhibition of 5-carboxytryptamine-induced cAMP elevation at 1 uM2008Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8
(Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists.
AID1274961Antidepressant activity in C57BL/6J mouse assessed as immobility time at 1.25 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 160.7 +/- 12 to 170.6 +/- 9 sec)2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1374546Antidepressant-like activity in Swiss albino mouse assessed as decrease in immobility time at 10 mg/kg, ip administered 30 mins prior to test measured for last 4 mins of 6 mins observation by forced swim test2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
AID1274957Antidepressant activity in C57BL/6J mouse assessed as number of events at 10 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 1325.1 +/- 77.8 to 1773.4 +/- 109.9 No_unit)2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1817200Effect on wild type mouse assessed as time taken for duration of self grooming at 30 mg/kg, ip after 30 mins under 40 lux lighting (Rvb = 43.7 +/- 10.8 sec)2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of G Protein-Biased Ligands against 5-HT
AID1517164Displacement of [3H]-5-HT from human 5HT7 receptor expressed in CHO-K1 cells incubated for 40 mins in presence of serotonin by liquid scintillation counter2019European journal of medicinal chemistry, Dec-01, Volume: 183[1]Benzothieno[3,2-d]pyrimidine derivatives as ligands for the serotonergic 5-HT
AID4279Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID6654Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Atropisomeric derivatives of 2',6'-disubstituted (R)-11-phenylaporphine: selective serotonin 5-HT(7) receptor antagonists.
AID386650Antagonist activity at 5HT7 receptor assessed as inhibition of 5-carboxamidotryptamine mediated relaxation of substance P-induced Dunkin-Hartley guinea pig ileum contraction2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III.
AID327995Antagonist activity at human 5HT7A receptor expressed in CHO cells assessed as inhibition of 5-carboxytryptamine-induced cAMP elevation at 10 nM administered before 5-carboxytryptamine challenge2008Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8
(Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists.
AID5775Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID236592pKa 2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides.
AID1769140Binding affinity to 5HT1A receptor (unknown origin)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID1380717Antagonist activity at human 5-HT7 receptor expressed in CHO-K1 cells assessed as decrease in serotonin-induced cAMP level after 1 hr by TR-FRET assay relative to control
AID433129Binding affinity to 5HT2A receptor in rat cortex2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Sulfonamides with the N-alkyl-N'-dialkylguanidine moiety as 5-HT7 receptor ligands.
AID1384701Inverse agonist activity at human 5-HT7 receptor expressed in HEK293 cells assessed as decrease in Gs protein-mediated cAMP accumulation by luminescence-based assay
AID1769145Binding affinity to 5HT2B receptor (unknown origin)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID694795Displacement of [3H]-8-OH-DPAT from human 5-HT1A receptor expressed in HEK293 cells after 1 hr2012European journal of medicinal chemistry, Oct, Volume: 56The multiobjective based design, synthesis and evaluation of the arylsulfonamide/amide derivatives of aryloxyethyl- and arylthioethyl- piperidines and pyrrolidines as a novel class of potent 5-HT₇ receptor antagonists.
AID1336983Displacement of [3H]-8-OH-DPAT from recombinant human 5-HT1A receptor expressed in CHOK1 cell membranes after 1 hr by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
New N- and O-arylpiperazinylalkyl pyrimidines and 2-methylquinazolines derivatives as 5-HT
AID1384578Binding affinity to human 5-HT7 receptor by radioligand binding assay2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
Structure-Activity Relationships and Therapeutic Potentials of 5-HT
AID745115Binding affinity to 5HT7 receptor (unknown origin)2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
Discovery of aryl-biphenyl-2-ylmethylpiperazines as novel scaffolds for 5-HT(7) ligands and role of the aromatic substituents in binding to the target receptor.
AID65313Binding affinity towards Dopamine receptor D3 (human cloned receptor) in CHO cells using [125I]iodosulpiride radioligand.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID1274948Antidepressant activity in C57BL/6J mouse assessed as average force at 2.5 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 0.281 +/- 0.018 to 0.359 +/- 0.027 N)2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID238569Binding affinity towards rat 5-HT7 receptor expressed in HEK cells2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides.
AID628904Antidepressant like activity in Albino Swiss mouse assessed as reduction of immobility time at 20 mg/kg, ip administered 30 mins before test measured during final 4 mins of the 6 mins session by forced swimming test (Rvb = 165 +/- 9.6 sec)2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands.
AID296896Antagonist activity at 5HT7 receptor in guinea pig ileum assessed as effect on 4-[2-(1-methylethyl)phenyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazine hexanamide mediated relaxation of substance P-induced contraction2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
AID1384704Agonist activity at tTA containing TCS cleavage site-fused 5-HT7 receptor (unknown origin) expressed in tTA-dependent luciferase reporter/TEV-fused beta-arrestin2 expressing HTLA cells assessed as induction of beta-arrestin2 recruitment after 22 hrs by Ta
AID1769167Effect on shank3-/- mouse model of autism spectrum disorder assessed as reduction in duration of self grooming at 5 mg/kg, ip after 30 mins (Rvb = 280 +/- 29.4 sec)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID1769149Binding affinity to 5HT5A receptor (unknown origin)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID552758Binding affinity to 5HT7 receptor2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Novel tetrahydropyrido[3,2-c]pyrroles as 5-HT(7) antagonists.
AID433128Binding affinity to 5HT1A receptor in rat hippocampus2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Sulfonamides with the N-alkyl-N'-dialkylguanidine moiety as 5-HT7 receptor ligands.
AID1364782Antidepressant-like activity in C57BL/6J mouse at 2.5 mg/kg measured during 6 mins session by tail suspension test
AID1274944Toxicity in ip dosed Wistar rat assessed as effect on spontaneous locomotory activity at MED measured over 2 to 6 mins2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1330691Antagonist activity at human 5-HT7R expressed in HEK293 cells assessed as inhibition of serotonin stimulated cAMP levels at 10 uM preincubated for 10 mins followed by serotonin stimulation after 30 mins by D2-dye based fluorescence assay2016European journal of medicinal chemistry, Nov-10, Volume: 1235-HT7 receptor modulators: Amino groups attached to biphenyl scaffold determine functional activity.
AID4957Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID1769148Binding affinity to 5HT4 receptor (unknown origin)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID1374550Antidepressant-like activity in Wistar rat assessed as decrease in immobility time at 1.25 mg/kg, ip administered 30 mins prior to test measured for 5 mins by forced swim test2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
AID5424Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID1364788Antidepressant-like activity in Swiss albino mouse assessed as decrease in immobility time at 2.5 to 20 mg/kg cotreated with dopamine reuptake inhibitor GBR-12909 measured during last 4 mins of 6 mins test by forced swim test
AID5655Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID1545645Antagonist activity at human recombinant 5-HT7 receptor expressed in CHOK1 cells measured after 60 mins in the presence of serotonin by LANCE TR-FRET assay2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
AID4989Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID1546007Antagonist activity at 5-HT1A receptor (unknown origin)2019European journal of medicinal chemistry, Dec-01, Volume: 183Structure-activity relationships of serotonin 5-HT
AID1384579Selectivity for human 5-HT7 receptor over 5-HT1A receptor (unknown origin)2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
Structure-Activity Relationships and Therapeutic Potentials of 5-HT
AID1274950Antidepressant activity in C57BL/6J mouse assessed as average force at 10 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 0.281 +/- 0.018 to 0.359 +/- 0.027 N)2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1193846Displacement of [3H]-8-OH-DPAT from human 5-HT7 receptor expressed in CHOK1 cells after 30 mins by liquid scintillation counting analysis2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis and binding properties of new long-chain 4-substituted piperazine derivatives as 5-HT₁A and 5-HT₇ receptor ligands.
AID1324270Displacement of [3H]-ketanserin from human 5-HT2A receptor expressed in HEK293 cells2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.
AID4108Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Atropisomeric derivatives of 2',6'-disubstituted (R)-11-phenylaporphine: selective serotonin 5-HT(7) receptor antagonists.
AID1324271Displacement of [3H]-5-CT from human 5-HT7a receptor expressed in HEK293 cells2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.
AID1152673Antagonist activity at human 5-HT7 receptor expressed in CHO-K1 cells assessed as inhibition of serotonin-induced cAMP accumulation after 60 mins by TR-FRET immunoassay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
AID296893Antagonist activity at 5HT7 receptor in guinea pig ileum assessed as effect on 6-(4-phenylpiperazin-1-yl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide mediated relaxation of substance P-induced contraction2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
AID1336982Displacement of [3H]-5-HT from recombinant human 5-HT7A receptor expressed in CHOK1 cell membranes after 40 mins by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
New N- and O-arylpiperazinylalkyl pyrimidines and 2-methylquinazolines derivatives as 5-HT
AID1274969Antidepressant activity in albino Swiss mouse assessed as decrease in immobility time at 10 mg/kg, ip by forced swim test2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1769150Binding affinity to 5HT6 receptor (unknown origin)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID6667Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.
AID1364775Antidepressant-like activity in Swiss albino mouse assessed as decrease in immobility time at 10 mg/kg measured during last 4 mins of 6 mins test by forced swim test relative to control
AID1769168Effect on wild type mouse assessed as reduction in number of self grooming at 5 mg/kg, ip after 30 mins (Rvb = 18 +/- 1.6 No_unit)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID296899Antagonist activity at 5HT7 receptor in guinea pig ileum assessed as effect on 3-(2-aminoethyl)-1H-indole-5-carboxamide mediated relaxation of substance P-induced contraction2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
AID6677Binding affinity towards human 5-hydroxytryptamine 7 receptor2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
AID1269156Antidepressant-like activity in Swiss albino mouse assessed as reduction in immobility time at 10 mg/kg, ip dosed 30 mins before test measured after 6 mins by forced swim test2016Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2
N-Alkylated arylsulfonamides of (aryloxy)ethyl piperidines: 5-HT(7) receptor selectivity versus multireceptor profile.
AID1278644Antagonist activity at human 5-HT7 receptor expressed in HEK293 cells assessed as inhibition of 5-HT-induced cAMP production at 10 uM pretreated for 10 mins followed by stimulation with 5-HT for 30 mins by fluorescence analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Novel N-acyl-carbazole derivatives as 5-HT7R antagonists.
AID386648Antagonist activity at 5HT7 receptor assessed as inhibition of 4-(2-Diphenyl)-N-(4-pyridinylmethyl)-1-piperazinehexanamide mediated relaxation of substance P-induced Dunkin-Hartley guinea pig ileum contraction2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III.
AID386647Antagonist activity at 5HT7 receptor assessed as inhibition of 2-[6-[4-(2-Diphenyl)-1-piperazinyl]-1-oxohexyl]-1,2,3,4-tetrahydroisoquinoline mediated relaxation of substance P-induced Dunkin-Hartley guinea pig ileum contraction2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III.
AID1627081Displacement of [3H]-8-OH-DPAT from human 5-HT1A receptor expressed in CHOK1 cell membranes after 30 mins by liquid scintillation spectrometry2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Design and synthesis of new homo and hetero bis-piperazinyl-1-propanone derivatives as 5-HT7R selective ligands over 5-HT1AR.
AID3926Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID1188131Displacement of [3H]8-OH-DPAT from human 5-HT1A receptor transfected in CFO-K1 cells after 30 mins by liquid scintillation spectrometry2014European journal of medicinal chemistry, Oct-06, Volume: 85Structure-activity relationships and molecular modeling studies of novel arylpiperazinylalkyl 2-benzoxazolones and 2-benzothiazolones as 5-HT(7) and 5-HT(1A) receptor ligands.
AID6463Binding affinity towards 5-hydroxytryptamine 4 receptor2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID1769144Binding affinity to 5HT2A receptor (unknown origin)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID1193852Binding affinity to human 5-HT1B receptor2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis and binding properties of new long-chain 4-substituted piperazine derivatives as 5-HT₁A and 5-HT₇ receptor ligands.
AID1769141Binding affinity to 5HT1B receptor (unknown origin)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID628903Antidepressant like activity in Albino Swiss mouse assessed as reduction of immobility time at 10 mg/kg, ip administered 30 mins before test measured during final 4 mins of the 6 mins session by forced swimming test (Rvb = 165 +/- 9.6 sec)2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands.
AID1374554Anxiolytic-like activity in Swiss albino mouse assessed as increase in number of punished crossings at 1 mg/kg, ip administered for 30 mins measured for 1 min post 3 sec electric shock by four-plate test2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
AID386646Antagonist activity at 5HT7 receptor assessed as inhibition of 6-(4-Biphenyl-2-yl-piperazin-1-yl)-hexanoic acid (1,2,3,4-tetrahydro-naphthalen-1-yl)-amide mediated relaxation of substance P-induced Dunkin-Hartley guinea pig ileum contraction2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III.
AID386649Antagonist activity at 5HT7 receptor assessed as inhibition of N-(4-Cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide mediated relaxation of substance P-induced Dunkin-Hartley guinea pig ileum contraction2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III.
AID1545639Antagonist activity at human recombinant 5-HT7 receptor expressed in CHOK1 cells measured after 60 mins in the presence of serotonin by LANCE TR-FRET assay relative to control2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
AID1193851Antagonist activity at human 5-HT1B receptor expressed in HEK293 cells assessed as inhibition of 5-CT-induced cAMP production at 1 uM after 30 mins by TR-FRET assay2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis and binding properties of new long-chain 4-substituted piperazine derivatives as 5-HT₁A and 5-HT₇ receptor ligands.
AID1769147Binding affinity to 5HT3 receptor (unknown origin)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of G Protein-Biased Antagonists against 5-HT
AID296898Antagonist activity at 5HT7 receptor in guinea pig ileum assessed as effect on 4-(2-dimethylaminophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazine hexanamide mediated relaxation of substance P-induced contraction2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
AID35178Binding affinity towards Alpha-1B adrenergic receptor2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
AID1274962Antidepressant activity in C57BL/6J mouse assessed as immobility time at 2.5 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 160.7 +/- 12 to 170.6 +/- 9 sec)2016European journal of medicinal chemistry, Jan-27, Volume: 108Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1546006Antagonist activity at 5-HT7 receptor (unknown origin)2019European journal of medicinal chemistry, Dec-01, Volume: 183Structure-activity relationships of serotonin 5-HT
AID6681Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
AID65736Displacement of [3H]raclopride from human dopamine receptor D2A expressed in mouse Ltk cells2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Atropisomeric derivatives of 2',6'-disubstituted (R)-11-phenylaporphine: selective serotonin 5-HT(7) receptor antagonists.
AID628905Antidepressant like activity in Albino Swiss mouse assessed as reduction in immobility time at 10 mg/kg, ip administered 30 mins before test measured during final 4 mins of the 6 mins session by forced swimming test2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands.
AID1324272Displacement of [3H]-5-HT from human 5-HT2B receptor expressed in HEK293 cells2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1345291Human 5-HT7 receptor (5-Hydroxytryptamine receptors)2000British journal of pharmacology, May, Volume: 130, Issue:2
[(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (190)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's82 (43.16)29.6817
2010's92 (48.42)24.3611
2020's16 (8.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.61 (24.57)
Research Supply Index5.26 (2.92)
Research Growth Index6.23 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.04%)6.00%
Case Studies1 (0.52%)4.05%
Observational0 (0.00%)0.25%
Other189 (98.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]